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Abstract
Background:  Frontotemporal lobar degeneration (FTLD) consists of a clinically and
neuropathologically heterogeneous group of syndromes affecting the frontal and temporal lobes of
the brain. Mutations in microtubule-associated protein tau (MAPT), progranulin (PGRN) and charged
multi-vesicular body protein 2B (CHMP2B) are associated with familial forms of the disease. The
prevalence of these mutations varies between populations. The H1 haplotype of MAPT has been
found to be closely associated with tauopathies and with sporadic FTLD. Our aim was to investigate
MAPT mutations and haplotype frequencies in a clinical series of patients with FTLD in Northern
Finland.
Methods: MAPT exons 1, 2 and 9–13 were sequenced in 59 patients with FTLD, and MAPT
haplotypes were analysed in these patients, 122 patients with early onset Alzheimer's disease
(eoAD) and 198 healthy controls.
Results: No pathogenic mutations were found. The H2 allele frequency was 11.0% (P = 0.028) in
the FTLD patients, 9.8% (P = 0.029) in the eoAD patients and 5.3% in the controls. The H2 allele
was especially clustered in patients with a positive family history (P = 0.011) but did not lower the
age at onset of the disease. The ApoE4 allele frequency was significantly increased in the patients
with eoAD and in those with FTLD.
Conclusion: We conclude that although pathogenic MAPT mutations are rare in Northern Finland,
the MAPT H2 allele may be associated with increased risks of FTLD and eoAD in the Finnish
population.
Background
Frontotemporal lobar degeneration (FTLD) is a clinically
and neuropathologically heterogeneous group of neuro-
degenerative disorders affecting the frontal and/or tempo-
ral lobes and causing changes in personal and social
conduct, disinhibition and progressive changes in lan-
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guage. The main clinical syndromes are frontotemporal
dementia (FTD), semantic dementia (SD) and progressive
non-fluent aphasia (PA).[1] FTLD can be divided neu-
ropathologically into diseases with tau-positive inclusions
and diseases with tau-negative and ubiquitin-positive
inclusions.[2] A positive family history is present in 30–
50% of FTLD cases.[3,4] Mutations in microtubule-associ-
ated protein tau (MAPT), progranulin (PGRN)  and
charged multi-vesicular body protein 2B (CHMP2B) are
associated with the autosomal dominant form of the dis-
ease. [5-9]
Mutations in MAPT are associated with tau-positive neu-
ropathology and occur in familial FTLD in frequencies
that vary in the range 5–50% between populations.[3,10-
15] Several polymorphisms throughout the MAPT gene
are in complete linkage disequilibrium with each other
and are inherited as two separate haplotypes, H1 and H2.
The predominant haplotype, H1, has been found to be
associated with sporadic tauopathies, [16-18] and also to
have a faint association with FTLD.[19,20] However, in
some studies the H2 haplotype has also been found to be
associated with FTLD.[15,21]
The aim of this work was to investigate the frequency of
MAPT mutations in Finnish patients with FTLD and to
examine the association between the MAPT haplotypes
and FTLD. We sequenced exons 1, 2 and 9–13 of MAPT in
59 Finnish patients with FTLD and analysed the MAPT
haplotypes in these patients, 122 patients with early onset
Alzheimer's disease (eoAD, age at onset before 65 years)
and 198 healthy middle-aged controls.
Methods
Patients
We examined 59 patients with FTLD (mean age at onset
58.5 years, range 38–79, 49% men) and 122 patients with
eoAD (mean age 58.2 years, range 38–64, 45% men) in
the memory clinic of the Department of Neurology, Oulu
University Hospital, Finland, during the years 1999–
2006. Population of the Northern Ostrobothnia area
served by this hospital was 380 668 (as of 31.12.2006). A
clinical diagnosis of FTLD was made according to the cri-
teria of Lund and Manchester, and the NINCDS-ADRDA
criteria were used to establish a diagnosis of probable
AD.[22,23] The FTLD group consisted of 34 (58%)
patients with FTD, 19 (32%) with PA and six (10%) with
SD. Six patients (10%) also suffered from symptoms of
motor neuron disease. 27% of the patients in the FTLD
group had a positive family history of FTLD, i.e. a first-
degree relative suffering from dementia. PGRN gene
mutations in the FTLD patients were excluded by direct
sequencing as described previously.[24] Most of the
patients were alive during this study and neuropathologi-
cal examinations were performed only on five deceased
subjects.
Control samples were obtained from 198 healthy anony-
mous middle-aged volunteers (mean age 40.6 years, range
19–64 years) as part of blood donations at Finnish Red
Cross offices in the capitals of the provinces of Northern
and Central Ostrobothnia and Kainuu.
Written informed consent was obtained from all the
patients or their guardians. The research protocols were
approved by the Ethics Committees of the Faculty of Med-
icine at the University of Oulu, the Northern Ostroboth-
nia Hospital District and the Finnish Red Cross.
Methods
Total genomic DNA was extracted from the blood samples
by the standard sodium dodecyl sulphate-proteinase K
method. MAPT exons 1, 2 and 9–13 were amplified by
polymerase chain reaction using genomic primers
designed to cover the flanking intronic sequences as well.
These exons were selected, because pathogenic mutations
in MAPT have been associated to exons 1 and 9–13. Exon
2 was randomly selected to add data of polymorphisms
between H1 and H2 haplotypes. Sequencing was carried
out using the BigDye Terminator v1.1 Cycle Sequencing
Kit (Applied Biosystems) and the ABI PRISM 3100
Genetic Analyzer (Applied Biosystems).
The MAPT haplotype was determined by testing for the
presence of a 238 bp deletion between exons 9 and 10,
which is characteristic of the H2 haplotype.[25] The hap-
lotypes were assessed by visualizing the PCR products on
a 1.5% agarose gel.
A novel exon13 +67delAAT polymorphism was screened
by PCR using mismatch primers (forward 5'-GAGATCGT-
GTACAAGTCGCCAGT-3' and reverse 5'-AGAGGGCG-
GGGGCCGGGTCAAT-3'). The amplified fragments were
digested with SspI restriction enzyme and then visualized
using a 5% Metaphor gel. The apolipoprotein E (ApoE)
genotype was determined as described previously.[26]
Statistical analyses were performed using the SPSS 16.0
software for Windows. The minimum significance level
was set at P = 0.05. Differences in allele distributions were
analysed using the χ2 test. Fisher's exact test was used to
analyse contingency tables when the expected value was
less than five. Binary logistic regression analyses were per-
formed to estimate both the marginal and partial (i.e. cor-
recting for age, gender and ApoE4 allele) potential effects
of genetic patterns.BMC Neurology 2008, 8:48 http://www.biomedcentral.com/1471-2377/8/48
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Results
We sequenced exons 1, 2 and 9–13 of the MAPT gene in
59 Finnish patients with FTLD and analysed MAPT haplo-
types in these patients, 122 patients with eoAD and 198
middle-aged healthy controls. No pathogenic MAPT
mutations were found in the patients with FTLD.
We detected seven polymorphic sites which have previ-
ously been found to be associated with the H2 haplotype
(Table 1), but did not find any novel polymorphisms in
the H2 haplotype. The previously described Thr39Thr,
P270P, Exon10 -47 and Exon11 +90, Exon11 +104 poly-
morphisms were found to be associated with the H1 allele
(Table 2), in addition to a novel polymorphism Exon13
+67delAAT, which was found in 10 H1 alleles of patients
with FTLD. One H1/H1 homozygous patient was also
homozygous for the Exon13 +67delAAT polymorphism.
The frequencies of Exon13 +67delAAT were 9.5% among
the FTLD patients with the H1 allele, 8.5% in the whole
FTLD group, 5.9% in the AD patients and 3.2% in healthy
controls. Results of a neuropathological examination
were available for one man with this polymorphism, who
had had FTLD with ALS (amyotrophic lateralis sclerosis),
for six years with onset at the age of 59 years. These results
revealed tau-negative, ubiquitin-positive FTLD and motor
neuron disease.
The frequencies of the H2 allele were 11.0% in the
patients with FTLD and 9.8% in those with eoAD, as
opposed to 5.3% in the controls (Table 3). Thus the fre-
quencies of the H2 allele and the genotypes H1/H2 + H2/
H2 were significantly increased in the FTLD patients rela-
tive to the controls (Table 3 and Table 4), and they also
showed a significant increase among the patients with
eoAD. The H2 allele was clustered with the familial form
of FTLD, so that a positive family history was found in
58% of the FTLD cases with the H1/H2 or H2/H2 geno-
type (Fisher's exact test, P = 0.011). The H2 allele was not
associated with onset of the disease at an earlier age, the
age at onset being 56.0 ± 6.7 years (mean ± SD) in the H1/
H2 or H2/H2 carriers, and 59.2 ± 6.5 years in the H1/H1
carriers (P = 0.138).
Only one patient, with a negative family history of neuro-
logical disorders, had the H2/H2 genotype. In this case
progressive aphatic symptoms and changes in personality
had started at the age of 52 years and by the end-stage of
the disease he was completely aphatic and had evident
extrapyramidal symptoms. He died at the age of 62 years.
Neuropathological evaluation revealed marked atrophy
in both the frontal and temporal lobes. Tau-pathology
was widespread. Tangle-like, globose and granular neuro-
nal inclusions were present in neocortex, other than
occipitally, and in the hippocampal pyramidal and fascia
dentata neurones, basal ganglia, substantia nigra, locus
ceruleus and cerebellar dentate. Tau-positive neuropil
threads were seen in the same areas and in the subcortical
white matter, and some white matter glial cells were tau-
positive. Beta-amyloid and synuclein were absent.
The ApoE4 allele was found in 42.4% of the FTLD patients
and 63.1% of the eoAD patients, the latter frequency
being significantly increased (P < 0.001), but the former
less so (P = 0.049).
Discussion
We analysed MAPT mutations and the role of the MAPT
haplotype in 59 patients with FTLD in Northern Finland.
A positive family history was found in 27% of these
patients, but no pathogenic mutations in MAPT  were
detected. The relative frequency of MAPT mutations has
varied previously between 0 and 50% depending on type
of study, the area concerned and whether there has been a
family history of the disease, [4,10,12-14,27,28] although
the differences in frequency may also be explained by var-
ying methods of case ascertainment. The frequency is
obviously higher in familial forms of FTLD, however, an
effect that has been attributed to the founder mutation in
France and the Netherlands.[4,10,12] Interestingly, very
low frequencies of MAPT mutations have been reported in
Sweden and Poland.[27,28] The roots of the Finnish pop-
ulation reach back over 2000 years, but internal migration
to Northern Ostrobothnia in the 16th century created a
regional subisolate in the population of some 380000
inhabitants examined here,[29] which may explain the
extremely low MAPT mutation frequency. On the other
Table 1: Polymorphisms in the H2 haplotype
Exon Position Relative to Exon Codon Nucleotide Change
5' UTR -13 from ATG A > G
Exon 2 -93 T > C
+18 C > T
Exon 9 A227A GCA > GCG
N255N AAT > AAC
Exon 11 +34 G > A
Exon 13 +34 T > CBMC Neurology 2008, 8:48 http://www.biomedcentral.com/1471-2377/8/48
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hand, the geographical variation may reflect differences in
the prevalence of MAPT mutations between populations.
Our data support the findings of very low frequencies of
MAPT mutations in the Baltic countries.[27,28]
We found that the H2 allele frequencies in patients with
either FTLD or eoAD were two-fold compared with those
in the controls, and that the frequencies of both the H2
allele and the H1/H2 + H2/H2 genotypes were signifi-
cantly higher in both patient groups. The H2 allele in par-
ticular was associated with the familial form of FTLD. The
H1 haplotype is the most common, having an allele fre-
quency of about > 70% in European populations,[30]
while the H2 haplotype has been associated with Cauca-
sian ancestry, since Middle Eastern and European popula-
tions have frequencies of about 25%, the Finnish
population about 8% and Central Asian populations
about 5%, while the allele is essentially practically non-
existent in other populations.[30] H1 has been associated
with sporadic tauopathies, including Parkinson's dis-
ease,[16,17] progressive supranuclear palsy (PSP) and
corticobasal degeneration (CBD),[18] and it also has a
putative association with FTD.[19,20] In particular, the
H1c variant of the H1 haplotype has been linked with
CBD, PSP and AD.[18,31] Recently, however, the H2 hap-
lotype has been found to increase the risk of familial FTD
in an Italian population.[21] Two Belgian families with
FTLD have been linked with the extended rare H2 haplo-
type and a PGRN mutation.[7,15] However, no patho-
genic mutations in PGRN were found in our cohort.[24]
The H2 haplotype has also been reported to lower the age
of onset of the disease,[32] but this finding could not be
confirmed in the present study. Interestingly, this is the
first study showing the association between the H2 haplo-
type and Alzheimer's disease.
The H2 haplotype is assumed to be an ancestral one and
to manifest only minor variability,[18,33] as confirmed
here. A novel polymorphism Exon 13 +67 delAAT was
found to be associated with the H1 allele and to have an
increased frequency in patients with FTLD and eoAD,
although it was also frequent in the controls, thus suggest-
ing a non-pathogenic nature.
A significant association was found between the ApoE4
allele, the most important genetic risk factor for AD, and
eoAD, and a similar association was also evident with
FTLD. Increased frequency of the ApoE4 allele in patients
with FTLD has also been reported previously,[32,34] and
it has also been found to increase the penetrance of
dementia, since valosin-containing protein (VCP) is asso-
ciated with FTD,[35] and to impair long-term memory
functions and reduce parahippocampal perfusion in FTLD
patients.[36]
Conclusion
We conclude that, although pathogenic MAPT mutations
are rare in Northern Finland, the frequency of the H2
allele of MAPT is significantly increased in patients with
FTLD and also in patients with eoAD. Either the H2 hap-
Table 2: Polymorphisms in the H1 haplotype
Exon Position Relative to Exon Codon Nucleotide Change Allele Frequency in Patients with FTLD
Exon 1 T39T ACG > ACA 3
Exon 2 T52A ACT > GCT 1
Exon 9 P270P CCG > CCA 1
Exon 10 -47 C > A 2
Exon 11 +90 G > A 16
Exon 11 +104 A > G 1
Exon 13 +67 del AAT 10
Table 3: MAPT genotypes and haplotypes in patients with FTLD and eoAD
Sample Genotypes Haplotypes
N
Individuals
H1/H1
N (%)
H1/H2
N (%)
H2/H2
N (%)
Genotype vs. 
controlsb
N
Alleles
H1
N (%)
H2
N (%)
Haplotypes vs. 
controls
FTLD 59 47 (79.7) 11 (18.6) 1 (1.7) P = 0.018a 118 105 (89.0) 13 (11.0) P = 0.028a
EoAD 122 98 (80.3) 24 (19.7) 0 P = 0.006a 244 220 (90.2) 24 (9.8) P = 0.029a
Controls 198 180 (90.9) 15 (7.6) 3 (1.5) 396 375 (94.7) 21 (5.3)
a Indicates statistical significance
b The genotypes were grouped into H1/H1 and H1/H2 + H2/H2 for statistical analysisBMC Neurology 2008, 8:48 http://www.biomedcentral.com/1471-2377/8/48
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lotype itself or other genetic variations associated with it
may be a risk factor for FTLD and eoAD in the Finnish
population.
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